A non-steroidal anti-inflammatory drug (flurbiprofen) to control idiopathic hypercalciuria resistant to dietary manipulation.
Twenty-three calcium stone formers with idiopathic hypercalciuria were entered into an open study to examine the effects of flurbiprofen (Froben) on urinary calcium excretion. Five patients were withdrawn because of side effects. A statistically significant reduction in urinary calcium excretion was noted after 2 (P = 0.004) and 6 (P = 0.001) weeks' treatment. There was a significant increase in urinary calcium excretion after stopping the treatment (P = 0.0006). The results suggest that flurbiprofen reduces calcium excretion in the urine but the high incidence of side effects may limit its use in routine treatment of hypercalciuria.
D000328:Adult; D000368:Aged; D002118:Calcium / Q000652:urine; D002986:Clinical Trials as Topic; D004890:Erythema / Q000139:chemically induced; D005260:Female; D005480:Flurbiprofen / Q000009:adverse effects / Q000627:therapeutic use*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced; D011422:Propionates / Q000627:therapeutic use*; D013270:Stomach; D014545:Urinary Calculi / Q000188:drug therapy* / Q000652:urine
D011422:Propionates; D005480:Flurbiprofen; D002118:Calcium